Amneal Pharmaceuticals Advances Drug Development with Positive ELEVATE-PD Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 13 2026
0mins
Source: Yahoo Finance
- ELEVATE-PD Trial Results: Amneal Pharmaceuticals reported positive interim Phase 4 results from the ELEVATE-PD trial, indicating that CREXONT extended-release carbidopa/levodopa capsules significantly improved 'Good On' time, reduced 'Off' time, and enhanced motor scores in Parkinson's patients across various prior treatment regimens, thereby reinforcing its market position.
- FDA Approval of New Drug: Amneal secured FDA approval for a ready-to-use romidepsin injection, along with 180 days of Competitive Generic Therapy exclusivity, marking the return of this important oncology treatment to the U.S. market and highlighting the company's strategic shift towards higher-value complex products.
- Investment Narrative Shift: With the advancements in CREXONT's continuous 'Good On' intervals, Amneal's investment narrative is transitioning towards a more diversified portfolio of higher-value specialty, biosimilar, and complex products, although the company still faces significant generic price pressures and high leverage risks that could impact future growth.
- Financial Outlook: Amneal projects revenues of $3.7 billion and earnings of $325.7 million by 2029, with fair value estimates ranging from $11.94 to $82.75, reflecting divergent investor perspectives on the company's future performance and underscoring the need for a multifaceted approach in decision-making.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMRX
Wall Street analysts forecast AMRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.280
Low
13.00
Averages
14.33
High
15.00
Current: 16.280
Low
13.00
Averages
14.33
High
15.00
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amneal Pharmaceuticals Advances Drug Development with Positive ELEVATE-PD Results
- ELEVATE-PD Trial Results: Amneal Pharmaceuticals reported positive interim Phase 4 results from the ELEVATE-PD trial, indicating that CREXONT extended-release carbidopa/levodopa capsules significantly improved 'Good On' time, reduced 'Off' time, and enhanced motor scores in Parkinson's patients across various prior treatment regimens, thereby reinforcing its market position.
- FDA Approval of New Drug: Amneal secured FDA approval for a ready-to-use romidepsin injection, along with 180 days of Competitive Generic Therapy exclusivity, marking the return of this important oncology treatment to the U.S. market and highlighting the company's strategic shift towards higher-value complex products.
- Investment Narrative Shift: With the advancements in CREXONT's continuous 'Good On' intervals, Amneal's investment narrative is transitioning towards a more diversified portfolio of higher-value specialty, biosimilar, and complex products, although the company still faces significant generic price pressures and high leverage risks that could impact future growth.
- Financial Outlook: Amneal projects revenues of $3.7 billion and earnings of $325.7 million by 2029, with fair value estimates ranging from $11.94 to $82.75, reflecting divergent investor perspectives on the company's future performance and underscoring the need for a multifaceted approach in decision-making.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Amneal's Commitment to Reliable Medicine Supply for Uninsured Patients
- Strategic Initiative Launch: Amneal Pharmaceuticals has committed to supporting the 'Hope Alliance' campaign, aimed at providing high-quality, longer-dated medications for low-income and uninsured patients in the U.S., ensuring a reliable supply of critical chronic care therapies.
- Supply Chain Assurance: By contributing longer-dated medications from current production, Amneal helps break away from traditional short-term donation models, creating a more predictable supply chain that reduces health risks for patients due to medication shortages.
- Impactful Patient Stories: As illustrated by Valbai's experience, the consistent supply of medications has transformed her life, allowing her to care for her grandchildren, highlighting the importance of ongoing treatment for chronic patients and avoiding emergency room visits.
- Long-term Health Commitment: Amneal's participation reflects its dedication to expanding access to affordable medicines and, through collaboration with the 'Hope Alliance', ensures patients can consistently receive necessary treatments, promoting long-term health and stability.
See More
Amneal Supports Hope Alliance Campaign to Ensure Medicine Supply
- Strategic Initiative Launch: Amneal Pharmaceuticals has announced its support for the Dispensary of Hope's 'Hope Alliance' campaign, aimed at providing high-quality, long-dated medications to low-income and uninsured patients, ensuring a reliable supply of critical chronic care therapies.
- Supply Chain Innovation: The initiative moves beyond traditional short-dated donations by contributing longer-dated medications from current production, helping to establish a more predictable and sustainable supply chain that reduces health risks for patients due to medication shortages.
- Patient Impact Story: As illustrated by Valbai's experience, the lack of a stable medication supply has led to severe health issues, while the implementation of the 'Hope Alliance' campaign will provide ongoing treatment support for patients like her, significantly improving their quality of life.
- Commitment to Health Equity: Amneal's participation reflects its commitment to expanding access to affordable medications and promoting health equity by stabilizing medication supplies, ensuring that hundreds of thousands of uninsured patients can receive the treatments they need.
See More
CREXONT Phase 4 Study Shows Significant Clinical Benefits
- Significant Clinical Outcomes: The Phase 4 ELEVATE-PD study involving 214 patients demonstrated that switching to CREXONT® resulted in an average increase of 3.03 hours in daily 'Good On' time, indicating substantial improvements in motor function across various treatment groups.
- Enhanced Symptom Control: Patients switching to CREXONT experienced nearly doubled continuous 'Good On' intervals, increasing from a baseline of 3.19 hours to 6.27 hours, showcasing the drug's effectiveness in managing Parkinson's disease symptoms.
- Adverse Event Management: The most common treatment-emergent adverse events included dizziness (8.2%) and falls (6.9%), consistent with prior therapies, affirming the safety and efficacy profile of CREXONT.
- FDA Label Update: The recent FDA labeling update for CREXONT allows patients to sprinkle capsule contents on applesauce for easier administration, potentially increasing patient adherence and expanding market reach.
See More
Amneal Receives Approval for New Romidepsin Injection Solution
- Market Exclusivity: Amneal's romidepsin injection solution has received FDA approval and is designated as a Competitive Generic Therapy, granting it 180 days of market exclusivity, which will further solidify its leadership in the complex injectables market.
- Convenience Enhancement: The new romidepsin injection solution, available in a 27.5 mg/5.5 mL single-dose ready-to-use vial, eliminates the need for reconstitution, reducing preparation complexity for hospitals and pharmacies, thereby improving accuracy and consistency in patient dosing.
- Market Demand Fulfillment: This romidepsin injection solution is indicated for adult patients with cutaneous T-cell lymphoma who have received at least one prior systemic therapy, filling a market gap and reflecting Amneal's ongoing commitment to addressing the needs of hospitals and providers.
- Significant Sales Potential: According to IQVIA, the annual sales for romidepsin lyophilized powder were approximately $78 million for the 12 months ending April 2026, indicating that the new product is poised to achieve substantial sales performance in the market.
See More
Amneal Pharmaceuticals Advances Drug Development with Positive ELEVATE-PD Results
- ELEVATE-PD Trial Results: Amneal Pharmaceuticals reported positive interim Phase 4 results from the ELEVATE-PD trial, indicating that CREXONT extended-release carbidopa/levodopa capsules significantly improved 'Good On' time, reduced 'Off' time, and enhanced motor scores in Parkinson's patients across various prior treatment regimens, thereby reinforcing its market position.
- FDA Approval of New Drug: Amneal secured FDA approval for a ready-to-use romidepsin injection, along with 180 days of Competitive Generic Therapy exclusivity, marking the return of this important oncology treatment to the U.S. market and highlighting the company's strategic shift towards higher-value complex products.
- Investment Narrative Shift: With the advancements in CREXONT's continuous 'Good On' intervals, Amneal's investment narrative is transitioning towards a more diversified portfolio of higher-value specialty, biosimilar, and complex products, although the company still faces significant generic price pressures and high leverage risks that could impact future growth.
- Financial Outlook: Amneal projects revenues of $3.7 billion and earnings of $325.7 million by 2029, with fair value estimates ranging from $11.94 to $82.75, reflecting divergent investor perspectives on the company's future performance and underscoring the need for a multifaceted approach in decision-making.
See More
Biotech Sector Sees Surge in FDA and Global Approvals
- FDA Approval Boosts Innovation: Guardant Health (GH) secured FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS, highlighting the growing importance of liquid biopsy in advanced cancer treatment, which is expected to drive GH's market share growth.
- Therapy Expansion: Eli Lilly (LLY) received FDA approval for an every-eight-week maintenance dose of EBGLYSS, with Q1 2026 sales surging 141% to $145 million, reflecting strong demand in its immunology portfolio and further solidifying the company's market position.
- China Market Breakthrough: Vor Bio (VOR) announced that Telitacicept received approval from China's NMPA, becoming the only approved therapy for Sjögren's disease in the country, supported by positive Phase 3 trial data, which is expected to significantly improve patient quality of life and expand market reach.
- EU Approval for New Therapy: Sanofi (SNY) secured European Commission approval for Sarclisa in newly diagnosed multiple myeloma patients, based on Phase 3 IRAKLIA trial results, which is expected to enhance Sarclisa's application range and strengthen the company's competitiveness in blood cancer treatment.
See More
Amneal's Commitment to Reliable Medicine Supply for Uninsured Patients
- Strategic Initiative Launch: Amneal Pharmaceuticals has committed to supporting the 'Hope Alliance' campaign, aimed at providing high-quality, longer-dated medications for low-income and uninsured patients in the U.S., ensuring a reliable supply of critical chronic care therapies.
- Supply Chain Assurance: By contributing longer-dated medications from current production, Amneal helps break away from traditional short-term donation models, creating a more predictable supply chain that reduces health risks for patients due to medication shortages.
- Impactful Patient Stories: As illustrated by Valbai's experience, the consistent supply of medications has transformed her life, allowing her to care for her grandchildren, highlighting the importance of ongoing treatment for chronic patients and avoiding emergency room visits.
- Long-term Health Commitment: Amneal's participation reflects its dedication to expanding access to affordable medicines and, through collaboration with the 'Hope Alliance', ensures patients can consistently receive necessary treatments, promoting long-term health and stability.
See More
Amneal Supports Hope Alliance Campaign to Ensure Medicine Supply
- Strategic Initiative Launch: Amneal Pharmaceuticals has announced its support for the Dispensary of Hope's 'Hope Alliance' campaign, aimed at providing high-quality, long-dated medications to low-income and uninsured patients, ensuring a reliable supply of critical chronic care therapies.
- Supply Chain Innovation: The initiative moves beyond traditional short-dated donations by contributing longer-dated medications from current production, helping to establish a more predictable and sustainable supply chain that reduces health risks for patients due to medication shortages.
- Patient Impact Story: As illustrated by Valbai's experience, the lack of a stable medication supply has led to severe health issues, while the implementation of the 'Hope Alliance' campaign will provide ongoing treatment support for patients like her, significantly improving their quality of life.
- Commitment to Health Equity: Amneal's participation reflects its commitment to expanding access to affordable medications and promoting health equity by stabilizing medication supplies, ensuring that hundreds of thousands of uninsured patients can receive the treatments they need.
See More
CREXONT Phase 4 Study Shows Significant Clinical Benefits
- Significant Clinical Outcomes: The Phase 4 ELEVATE-PD study involving 214 patients demonstrated that switching to CREXONT® resulted in an average increase of 3.03 hours in daily 'Good On' time, indicating substantial improvements in motor function across various treatment groups.
- Enhanced Symptom Control: Patients switching to CREXONT experienced nearly doubled continuous 'Good On' intervals, increasing from a baseline of 3.19 hours to 6.27 hours, showcasing the drug's effectiveness in managing Parkinson's disease symptoms.
- Adverse Event Management: The most common treatment-emergent adverse events included dizziness (8.2%) and falls (6.9%), consistent with prior therapies, affirming the safety and efficacy profile of CREXONT.
- FDA Label Update: The recent FDA labeling update for CREXONT allows patients to sprinkle capsule contents on applesauce for easier administration, potentially increasing patient adherence and expanding market reach.
See More
Amneal Receives Approval for New Romidepsin Injection Solution
- Market Exclusivity: Amneal's romidepsin injection solution has received FDA approval and is designated as a Competitive Generic Therapy, granting it 180 days of market exclusivity, which will further solidify its leadership in the complex injectables market.
- Convenience Enhancement: The new romidepsin injection solution, available in a 27.5 mg/5.5 mL single-dose ready-to-use vial, eliminates the need for reconstitution, reducing preparation complexity for hospitals and pharmacies, thereby improving accuracy and consistency in patient dosing.
- Market Demand Fulfillment: This romidepsin injection solution is indicated for adult patients with cutaneous T-cell lymphoma who have received at least one prior systemic therapy, filling a market gap and reflecting Amneal's ongoing commitment to addressing the needs of hospitals and providers.
- Significant Sales Potential: According to IQVIA, the annual sales for romidepsin lyophilized powder were approximately $78 million for the 12 months ending April 2026, indicating that the new product is poised to achieve substantial sales performance in the market.
See More
